Oliver Kong
Observed names: O Kong, O. Kong
Institutions: Universidad Complutense de Madrid, Novartis (Switzerland), BC Cancer Agency, The University of Texas MD Anderson Cancer Center, Harvard University, Seoul National University, University of Ottawa, University of California, Los Angeles, Curtin University, Severance Hospital, Universitair Ziekenhuis Leuven, Ottawa Hospital, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Seoul National University Hospital, The Netherlands Cancer Institute, NYU Langone Health, Massachusetts General Hospital, Sarah Cannon, Centre Léon Bérard, Highlands Oncology Group, National Taiwan University Hospital, Tennessee Oncology, National Cancer Centre Singapore, Yonsei University Health System, UCLA Jonsson Comprehensive Cancer Center, Instituto de Seguridad Social del Estado de México y Municipios, Ludwig-Maximilians-Universität München
Observed institutions: Universidad Complutense de Madrid, Novartis (Switzerland), BC Cancer Agency, The University of Texas MD Anderson Cancer Center, Harvard University, Seoul National University, University of Ottawa, University of California, Los Angeles, University of California, San Francisco, Curtin University, Severance Hospital, Universitair Ziekenhuis Leuven, Ottawa Hospital, Ronald Reagan UCLA Medical Center, UCLA Medical Center, Seoul National University Hospital, The Netherlands Cancer Institute, NYU Langone Health, Massachusetts General Hospital, Novartis (France), Sarah Cannon, Centre Léon Bérard, Highlands Oncology Group, Novartis (United States), Royal Marsden Hospital, National Taiwan University Hospital, Tennessee Oncology, National Cancer Centre Singapore, Yonsei University Health System, Celgene (United States), UCLA Jonsson Comprehensive Cancer Center, Instituto de Seguridad Social del Estado de México y Municipios, Ludwig-Maximilians-Universität München
OpenAlex ID: A5082680413